Janux Therapeutics’ shares closed up 14% at $15.14, after it announced a collaboration and exclusive worldwide license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback